================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarter ended August 31, 2000
OR
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from ____________ to ____________
Commission File No. 1-11047
SPARTA SURGICAL CORPORATION
---------------------------
(Exact name of small business issuer in its charter)
Delaware 22-2870438
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
Olsen Centre
2100 Meridian Park Blvd., Concord, CA 94520
-------------------------------------------
(Address of principal executive offices)
(925) 825-8151
--------------
(Issuer's telephone number)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes X No ___
As of August 31, 2000, 8,796,194 shares of Common Stock, 82,533 shares of
Convertible Redeemable Preferred Stock, 28,068 shares of Series A Convertible
Redeemable Preferred Stock and 39,938 shares of Series AA Convertible Redeemable
Preferred Stock were outstanding.
================================================================================
<PAGE>
SPARTA SURGICAL CORPORATION
Form 10-QSB
INDEX
Page
Number
------
Part I. Financial Information
Item 1. Financial Statements
Consolidated Balance Sheet 3
as of August 31, 2000
Consolidated Statements 4
of Operations for the three months and six
months ended August 31, 2000 and 1999
Consolidated Statements 5
of Cash Flows for the six months
ended August 31, 2000 and 1999
Notes to Consolidated Financial Statements 6
Item 2. Management's Discussion and 7 - 10
Analysis of Financial Condition
and Results of Operations
Part II. Other Information and Signatures 11
-2-
<PAGE>
<TABLE>
<CAPTION>
SPARTA SURGICAL CORPORATION
CONSOLIDATED BALANCE SHEET
August 31, 2000
(Unaudited)
ASSETS
<S> <C>
Current assets:
Cash and cash equivalents $ --
Accounts receivable - net of allowance
for doubtful accounts of $44,000 431,000
Inventories 2,742,000
Other 77,000
------------
Total current assets 3,250,000
------------
Property and equipment, at cost:
Equipment 1,101,000
Other 18,000
------------
1,119,000
Less accumulated depreciation (370,000)
------------
Net property and equipment 749,000
------------
Other assets:
Intangible assets 932,000
Other 116,000
------------
Total other assets 1,048,000
------------
Total assets $ 5,047,000
------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long term obligations $ 130,000
Accounts payable - trade 1,010,000
Accrued expenses 161,000
------------
Total current liabilities 1,301,000
------------
Revolving credit facility and long term obligations 2,082,000
Stockholders' equity:
Preferred stock: $4.00 par value, 2,000,000 shares authorized;
1992 non-cumulative convertible redeemable preferred stock:
165,000 shares authorized, 82,533 shares issued and outstanding 330,000
Series A cumulative convertible redeemable preferred stock:
30,000 shares authorized, 28,068 shares issued and outstanding 112,000
Series AA cumulative convertible redeemable preferred stock:
875,000 shares authorized, 39,938 shares issued and outstanding 160,000
Common stock: $0.002 par value, 25,000,000 shares authorized,
8,796,194 shares issued and outstanding 14,000
Additional paid in capital 13,898,000
Accumulated deficit (12,850,000)
------------
Total stockholders' equity 1,664,000
------------
Total liabilities and stockholders' equity $ 5,047,000
------------
See accompanying notes to consolidated financial statements.
-3-
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
SPARTA SURGICAL CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Six Months Ended
August 31 August 31
-------------------------- --------------------------
2000 1999 2000 1999
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net sales $ 876,000 $ 965,000 $ 1,781,000 $ 1,364,000
Cost of sales 466,000 308,000 952,000 493,000
----------- ----------- ----------- -----------
Gross profit 410,000 657,000 829,000 871,000
Selling, general and administrative expenses 425,000 463,000 847,000 610,000
Research, development, and engineering 105,000 -- 224,000 --
Depreciation and amortization expenses 224,000 55,000 280,000 114,000
----------- ----------- ----------- -----------
Income (loss) from operations (344,000) 139,000 (522,000) 147,000
----------- ----------- ----------- -----------
Other income (expense):
Interest expense (85,000) (86,000) (165,000) (172,000)
----------- ----------- ----------- -----------
Net income (loss) (429,000) 53,000 (687,000) (25,000)
=========== =========== =========== ===========
Preferred stock dividends (17,000) (4,000) (21,000) (15,000)
----------- ----------- ----------- -----------
Net income (loss) applicable
to common stockholders $ (446,000) $ 49,000 $ (708,000) $ (40,000)
=========== =========== =========== ===========
Shares used to calculate basic net income (loss)
per common share 6,891,808 2,474,835 6,478,788 2,206,351
=========== =========== =========== ===========
Basic net income (loss) per common share $ (0.06) $ 0.02 $ (0.11) $ (0.02)
=========== =========== =========== ===========
Shares used to calculate diluted net income (loss)
per common share 6,891,808 4,040,409 6,478,788 2,206,351
=========== =========== =========== ===========
Basic net income (loss) per common share $ (0.06) $ 0.01 $ (0.11) $ (0.02)
=========== =========== =========== ===========
See accompanying notes to consolidated financial statements.
-4-
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
SPARTA SURGICAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended
August 31,
--------------------------
2000 1999
----------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss) $ (687,000) $ (25,000)
Adjustments to reconcile net income (loss) to net cash used by
Operating activities:
Depreciation and amortization 280,000 114,000
Gain on lease settlement -- (12,000)
Changes in operating assets and liabilities:
Accounts receivable (26,000) (204,000)
Inventories (92,000) 12,000
Other assets 226,000 65,000
Accounts payable and accrued expenses (278,000) (310,000)
----------- -----------
Net cash used in operating activities (577,000) (360,000)
Cash flows from investing activities:
Capital expenditures (11,000) (57,000)
Increase in intangible assets (65,000) (99,000)
----------- -----------
Net cash used in investing activities (76,000) (156,000)
Cash flows from financing activities:
Proceeds from Sale of common stock 381,000 125,000
Borrowing on revolving lines of credit and long term debt 2,122,000 1,451,000
Principal payments on long-term obligations (1,911,000) (1,060,000)
----------- -----------
Net cash provided by financing activities 592,000 516,000
----------- -----------
Net change in cash and cash equivalents (61,000) --
----------- -----------
Cash and cash equivalents at beginning of the period 61,000 1,000
----------- -----------
Cash and cash equivalents at end of the period $ -- $ 1,000
=========== ===========
Supplemental disclosure of cash flow information:
-------------------------------------------------
Cash paid during the year for:
Interest $ 171,000 $ 214,000
Income taxes -- --
Supplemental disclosure of non-cash financing activities:
---------------------------------------------------------
Dividends payable on Series A convertible redeemable preferred stock 17,000 14,000
Stock dividends paid on Series A convertible redeemable preferred stock 21,000 15,000
Issuance of common stock in acquisition of subsidiary -- 800,000
Conversion of debt into common stock 200,000 --
See accompanying notes to consolidated financial statements.
-5-
</TABLE>
<PAGE>
SPARTA SURGICAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. The accompanying consolidated financial statements of the Company as of
August 31, 2000 and for the three and six months ended August 31, 2000 and
1999 have been prepared on the same basis as the audited financial
statements. In the opinion of management, such unaudited information
includes all adjustments (consisting only of normal recurring accruals)
necessary for a fair presentation of this interim information. Operating
results and cash flows for interim periods are not necessarily indicative
of results for the entire year. The information included in this report
should be read in conjunction with the Company's audited financial
statements and notes thereto included in the Company's Annual Report on
Form 10-KSB for the year ended February 29, 2000, previously filed with the
Securities and Exchange Commission.
2. Basic income (loss) per share is based upon weighted average number of
common shares outstanding during the period. Diluted income (loss) per
share is computed using the weighted average number of common shares and
potentially dilutive securities outstanding during the period. Potentially
dilutive securities include incremental common shares issuable upon
conversion of convertible securities (using the if-converted method) and
shares issuable upon the exercise of stock options and warrants (using the
if-converted method). Potentially dilutive securities are excluded from the
computation if their effect is anti-dilutive. Contingently issuable shares
are included in diluted earnings per share when the related conditions are
satisfied. Potentially dilutive securities, excluded because of their
anti-dilutive effect, are 4,487,540 options and warrants, and 230,621
equivalent common shares of convertible preferred stock at August 31, 2000.
The following table sets forth the computation of basic and diluted net
income (loss) per common share:
<TABLE>
<CAPTION>
Three Months Ended August 31, Six Months Ended August 31,
----------------------------- ---------------------------
2000 1999 2000 1999
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Numerator
Net income (loss)
applicable to common stockholders ($ 446,000) $ 49,000 ($ 708,000) ($ 40,000)
Denominator
Weighted average common shares
outstanding during the period 8,794,794 3,427,821 8,381,774 3,159,337
Less shares in escrow 1,902,986 952,986 1,902,986 952,986
Shares used in computing basic income
(loss) per common share 6,891,808 2,474,835 6,478,788 2,206,351
Dilutive effect of conversion of preferred stock -- 233,074 -- --
Dilutive effect of options and warrants -- 602,812 -- --
Dilutive effect of convertible debt -- 729,688 -- --
----------- ----------- ----------- -----------
Shares used in computing diluted income
(loss) per common share 6,891,808 4,040,409 6,478,788 2,206,351
=========== =========== =========== ===========
</TABLE>
-6-
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Except for the historical information contained herein, the matters set
forth in this report are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks and uncertainties
from time to time in our periodic reports filed with the Securities and Exchange
Commission, including our Annual Report on Form 10-KSB, Quarterly Reports on
Form 10-QSB and other periodic filings. These forward-looking statements speak
only as of the date hereof. We disclaim any intent or obligation to update these
forward-looking statements.
The following important factors, among others, could cause actual results
to differ materially from those contained in forward-looking statements made in
this Form 10-QSB, or presented elsewhere by management from time to time. We
wish to caution stockholders and investors that the following important factors,
among others, in some cases have affected, and in the future could affect, our
actual results and could cause our actual results to differ materially from
those expressed in any forward looking statements made by us. The statements
under this caption are intended to serve as cautionary statements within the
scope of the Private Securities Litigation Reformation Act of 1995. The
following information is not intended to limit in any way the characterization
of other statements or information under other captions as cautionary statements
for such purpose. These factors could have a material adverse effect on our
business, operating results and financial condition. There can be no assurance
that our Company (i) can predict the market acceptance of our products, (ii)
will not face intense competition, (iii) will be able to obtain patent
protection for our products and preserve our trade secrets, (iv) will continue
the operations, as we may need additional financing and such financing may not
be available as we are highly leveraged and may be unable to service our debt,
(v) will be successful because we are subject to stringent and continuing
applicable federal regulations and may be subject to product liability claims,
(vi) will be able to retain or hire key personnel, and (vii) will successfully
generate sufficient revenue to achieve profitability from our new subsidiary,
Sparta E*Med, Inc.
Our results of operations vary significantly from year to year and from
quarter to quarter, and we depend on, among other factors, developing new
products, demand for our products and significantly depend on availability of
materials from our suppliers, and we also depend on our customers including
hospitals, physicians, distributors and OEM private label accounts. We have
incurred net losses in the past and can't assure future profitability.
RESULTS OF OPERATIONS
Three Months Ended August 31, 2000
As Compared to Three Months Ended August 31, 1999
Net sales for the three months ended August 31, 2000 ("Second Quarter
Fiscal 2001") were $876,000, a decrease of $89,000 or 9.2% from net sales of
$965,000 for the three months ended August 31, 1999 ("Second Quarter Fiscal
2000"). The decrease in net sales during the Second Quarter Fiscal 2001 as
compared to the Second Quarter Fiscal 2000 is primarily due to the decrease in
the electrotherapy business.
-7-
<PAGE>
Six Months Ended August 31, 2000
as Compared to Six Months Ended August 31, 1999
Net sales for the Six Months Ended August 31, 2000 ("Six Months Fiscal
2001") were $1,781,000, a 30.6% increase from net sales of $1,364,000 for the
Six Months Ended August 31, 1999 ("Six Months Fiscal 2000"). The net sales
increase of $417,000 during the Six Months Fiscal 2001 as compared to the Six
Months Fiscal 2000 can be primarily attributed to the inclusion of six months of
sales activity for electrosurgical in the Six Months Fiscal 2000 as compared to
three months of sales activity for electrosurgical in the Six Months Fiscal 1999
as a result of the purchase of Olsen Electrosurgical in June 1999, and securing
various orders from OEM kit packers and international distributors. Consistent
with our efforts to increase sales, in August 2000, we signed a two-year
exclusive distributorship agreement with Celestine International, Inc., to
market our electrosurgical instruments and accessories product line to Latin and
Central America and Mexico. Under the agreement, Celestine is appointed as
Sparta's Master Stocking Distributor.
Gross profit was $829,000 or 46.6% of net sales for the Six Months Fiscal
2001 as compared to $871,000 or 63.9% of net sales for the Six Months Fiscal
2000. The decrease in gross profit percentage is primarily due to special
contract prices recognized with OEM kit packers contracts and special
introductory CE Mark prices to new European distributors.
Selling, general and administrative ("SG&A") expenses for the Six Months
Fiscal 2001 were $847,000, an increase for SG&A expenses of $237,000 as compared
to $610,000 for the Six Months Fiscal 2000. The increase in SG&A expenses for
the Six Months Fiscal 2001 is partially due to certain fees expensed relating to
the acquisition of Olsen Electrosurgical, legal expenses in connection with the
Special Shareholders Meeting, the further development of Sparta E*Med.com and
attendance of various trade show activities to promote our products and increase
the promotion of our products to the European market under our recent CE Mark
approval.
Research, development and engineering ("RD&E") expenses for the Six Months
Fiscal 2001 were $224,000, as compared to no expenses for the Six Months Fiscal
2000. RD&E expenses are related to the further development of our MEESA product
and Sparta E*Med.com.
Depreciation and amortization ("D&A") expenses for the Six Months Fiscal
2001 were $280,000, a 145.6% increase from D&A expenses of $114,000 for the Six
Months Fiscal 2000. The increase of D&A expenses during the Six Months Fiscal
2001 is due to the amortization of $164,000 relating to the non-compete
agreement and goodwill in connection with the acquisition of Olsen
Electrosurgical in June 1999, of which $139,000 is an adjustment to reflect a
change in the estimated life of the covenant not to compete.
Total other expenses for the Six Months Fiscal 2001 was $165,000, a
decrease of $7,000 from total other expenses of $172,000 for the Six Months
Fiscal 2000. The decrease in total other expenses is primarily due to lower
banking expenses to the Company's primary lender.
As a result of the foregoing, the net loss for the Six Months Fiscal 2001
was $687,000, an increase of $662,000. The increase in net loss for the Six
Months Fiscal 2001 as compared to Six Months Fiscal 2000 is primarily due to the
increase of Research, development and engineering, and Selling, general and
administrative expenses, increase in depreciation and amortization relating to
the purchase of Olsen Electrosurgical and decrease in total other expenses as
discussed above.
-8-
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
Since inception, we have been undercapitalized and have experienced
financial difficulties. Our primary sources of working capital have been
revenues from operations, bank and private party loans and proceeds from the
sale of securities. Many of the bank and private party loans and certain of our
other obligations have required personal guarantees from Mr. Reiner, for which
he has been compensated by us. In addition, from time to time, Mr. Reiner has
provided us with the working capital in order to continue to operate our
business.
As of February 29, 2000, we had federal and state net operating loss carry
forwards of approximately $10,458,000. Our net operating loss carry forwards, if
not utilized, will expire at various dates through the year 2019.
Our working capital at August 31, 2000 was $1,949,000 as compared to
$1,633,000 at February 29, 2000, an increase of $316,000, which is primarily due
to the recently completed private equity placement.
On March 20, 2000 Bank of America Commercial provided us with an amended
24-month Revolving Line of Credit of up to $2,500,000 (the "Loan"). We agreed to
pay Bank of America Commercial interest on the average outstanding principal
amount of the Loan at a per annum rate of prime plus 3%. The Loan is advanced to
us based on a percentage of eligible assets and is secured by a first position
security interest on all our assets. In addition, $250,000 of the Loan is
personally guaranteed by Mr. Reiner. As of October 9, 2000, the outstanding
balance on the Loan was $1,649,000 and approximately $15,000 in credit was
available. The Loan is being used to provide working capital for current
operations. In connection with the financing, we issued Bank of America
Commercial a warrant to purchase up to 10,000 shares of our Common Stock
exercisable at $1.90 per share at any time until March 20, 2003.
From March 1999 through April 2000, we significantly improved our
Stockholders' Equity by adding equity through the combined conversion of
$1,285,000 of debt into shares of Common Stock and the purchase of Common Stock
in the amount of $1,263,125 under private placement memorandum, and we added an
additional $181,000 through the exercise of employee stock options. From Fiscal
Year Ended February 28, 1999 to Second Quarter Fiscal 2001, our Stockholders'
Equity increased from $222,000 to $1,664,000. We incurred expenses of
approximately $450,000 for finders and consultant fees, and legal and accounting
fees in connection with registration of securities issued under the private
placement memorandum and stock option exercises.
On September 22, 2000 we issued a private placement memorandum to raise
$1.5 million through the sale of 10% Subordinated Notes due October 1, 2001,
interest payable April 1, 2001 and October 1, 2001. Under the memorandum, the
investor will receive warrants to purchase one share of Sparta Surgical common
stock, par value $0.002, at $0.50 per share for each dollar of note purchased.
The warrants are for a period of three years with certain registration rights.
In addition, the investor will receive warrants to purchase 0.67 of one share of
common stock of Sparta E*Med, Inc., (a wholly owned subsidiary of Sparta
Surgical) par value $0.002 at $0.50 per share for each dollar of note purchased.
The warrants are for a period of three years with certain registration rights.
The proceeds of the private placement will be used for working capital and
targeted acquisitions, including Weck Electrosurgical. In addition, under the
terms of the private placement, we have the option to convert the principal
balance owing under the notes into common stock of Sparta Surgical, par value
$0.002, at $0.50 per share providing the closing ask price of our common stock
is at or above $1.25 per share on NASDAQ for ten consecutive trading days.
On May 23, 1997, Mr. Reiner and his Assignee provided the Company with a
Working Capital Credit Facility ("Reiner Facility") of up to $200,000 bearing
12% interest per annum. The Reiner Facility was subsequently increased to
$400,000. The advances and accrued interest made under the Reiner Facility was
due the ending of (i) May 1998, subsequently extended until June 30, 2001, or
(ii) upon the closing of a minimum of $1,000,000 equity or debt financing by the
Company, or (iii) upon default by the Company, or (iv) upon demand by Mr. Reiner
with a five days notice to the Company. In addition, Mr. Reiner has the option
to convert the outstanding loan balance into common stock, par value $0.002, at
75% discount of the average of the closing NASDAQ bid price of the five trading
days preceding the conversion date. Mr. Reiner has a junior lien on all of the
assets of the Company and is subordinated to its senior lender, Bank of America.
As of August 31, 2000, the amount due to Mr. Reiner under the Reiner Facility
was approximately $339,000 plus accrued interest of $6,191. Interest during the
Second Fiscal Quarter 2001 under the Reiner Facility totaled approximately
$8,500.
-9-
<PAGE>
In May 1998, we agreed to place into escrow 952,986 shares of common stock,
par value $0.002 for the benefit of Mr. Reiner and these shares would be
released from escrow to Mr. Reiner upon certain conditions specifically set
forth in the Escrow Agreement dated May 8, 1998. These shares were placed into
escrow as a consideration for Mr. Reiner agreeing to provide, (i) a personal
guarantee in an amount of $250,000 as to the obligations to its secured lender,
Bank of America, under its $2.5 million revolving credit facility, (ii) a
personal guarantee of approximately $715,000 of additional Company indebtedness
relating to certain leases and bridge loans, (iii) a $400,000 working capital
credit facility.
As of October 12, 2000, none of the conditions set forth in the Escrow
Agreement for the release of the shares from escrow have been met. Therefore,
the shares remain in escrow. Mr. Reiner has voting authority over the shares and
the shares are considered outstanding as of February 29, 2000, although for the
purposes of calculating the net loss per share, these shares are excluded. There
can be no assurance that the release from escrow and the issuance of these
shares to Mr. Reiner will not have a material adverse effect on our earnings.
Upon release of these shares from escrow to Mr. Reiner, assuming use of the fair
market value of our common stock on October 12, 2000, the charge to earnings
would be approximately $534,000.
Between September 1999 and November 1999, we agreed to place 950,000 shares
into escrow for the benefit of Mr. Reiner, as a condition of Mr. Reiner
providing (i) his personal guarantee of certain lease obligations and bank debt
in connection with the Company's acquisition of Olsen Electrosurgical, Inc. in
June 1999, (ii) a further extension of the repayment of the Reiner Facility due
June 30, 1999, to June 30, 2000. On June 30, 2000, the Company requested Mr.
Reiner to further extend the repayment of the Reiner Facility from June 30, 2000
for a period of 12 months to June 30, 2001. There can be no assurance that the
impact of these shares being placed into escrow and the release of these shares
to Mr. Reiner will not have a material adverse effect on our earnings. Upon
release of these shares from escrow to Mr. Reiner, assuming use of the fair
market value of our common stock on October 12, 2000, the charge to earnings
would be approximately $532,000.
In recent years, we have experienced losses from operations and continue to
suffer from a deficiency in available working capital. Revenues from existing
product lines have historically not been sufficient to generate adequate working
capital. We may need to raise additional funds in order to implement our
business plan, to find more aggressive marketing programs or to acquire
complementary businesses, technologies or services. Any required additional
funding may be unavailable on terms satisfactory to us, if at all. However,
there can be no assurance that we will be able to complete planned debt or
equity offerings. If we raise additional funds by issuing equity securities, we
may experience significant dilution and such securities may have no rights
senior to those of the holders of Common Stock. In addition, we provide no
assurance that our Common Stock will not become delisted from trading or is
ineligible for quotation due to changes in NASD listing requirements or if we
fail to comply with any rules and regulations pursuant to NASD rule 6530. All of
the aforementioned factors could have material adverse effect on our business,
operating results and financial conditions. Our ability to meet our planned
growth will require substantial cash resources. The timing and amount of future
capital requirements may vary significantly.
Except for the historical information contained herein, the matters set
forth in this report are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially. These risks are detailed
from time to time in the Company's periodic reports filed with the Securities
and Exchange Commission, including the Company's Annual Report on Form 10-KSB,
Quarterly Reports on Form 10-QSB and other periodic filings. These
forward-looking statements speak only as of the date hereof. The Company
disclaims any intent or obligation to update these forward-looking statements.
-10-
<PAGE>
Part II. Other Information
--------------------------
Item 1. Legal Proceedings
None
Item 2. Changes in Securities
None
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
A. Exhibit No.
27 Financial Data Schedule.
B. Reports on Forms 8-K
None
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Sparta Surgical Corporation
/s/ Thomas F. Reiner
--------------------
Thomas F. Reiner
Chairman of the Board
President & CEO
/s/ John O'Hanlon
-----------------
John O'Hanlon, CPA
Chief Financial Officer
(Principal Accounting Officer)
October 13, 2000
-11-
